SE0600091L - Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin - Google Patents

Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin

Info

Publication number
SE0600091L
SE0600091L SE0600091A SE0600091A SE0600091L SE 0600091 L SE0600091 L SE 0600091L SE 0600091 A SE0600091 A SE 0600091A SE 0600091 A SE0600091 A SE 0600091A SE 0600091 L SE0600091 L SE 0600091L
Authority
SE
Sweden
Prior art keywords
preparation
insulin
controlled release
dextran matrix
implant
Prior art date
Application number
SE0600091A
Other languages
English (en)
Swedish (sv)
Other versions
SE529040C2 (sv
Inventor
Vladimir A Sabetsky
Original Assignee
Bows Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37930329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0600091(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bows Pharmaceuticals Ag filed Critical Bows Pharmaceuticals Ag
Priority to SE0600091A priority Critical patent/SE0600091L/xx
Priority to US12/161,324 priority patent/US20080305139A1/en
Priority to HK09103041.4A priority patent/HK1125041B/en
Priority to DE602007003315T priority patent/DE602007003315D1/de
Priority to RU2008133635/15A priority patent/RU2008133635A/ru
Priority to EP09175832A priority patent/EP2153850A1/en
Priority to CNA2007800026635A priority patent/CN101370523A/zh
Priority to AT07709420T priority patent/ATE448798T1/de
Priority to BRPI0706543-4A priority patent/BRPI0706543A2/pt
Priority to EP07709420A priority patent/EP1973570B1/en
Priority to AU2007206087A priority patent/AU2007206087A1/en
Priority to MX2008008924A priority patent/MX2008008924A/es
Priority to CA002636173A priority patent/CA2636173A1/en
Priority to ES07709420T priority patent/ES2336380T3/es
Priority to JP2008551225A priority patent/JP2009523791A/ja
Priority to PCT/SE2007/050027 priority patent/WO2007084068A1/en
Priority to TW096101920A priority patent/TW200738279A/zh
Priority to ARP070100220A priority patent/AR059071A1/es
Publication of SE529040C2 publication Critical patent/SE529040C2/sv
Publication of SE0600091L publication Critical patent/SE0600091L/xx
Priority to US12/510,533 priority patent/US7781400B2/en
Priority to US12/724,158 priority patent/US20100172950A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
SE0600091A 2006-01-18 2006-01-18 Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin SE0600091L (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0600091A SE0600091L (sv) 2006-01-18 2006-01-18 Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin
PCT/SE2007/050027 WO2007084068A1 (en) 2006-01-18 2007-01-17 Pharmaceutical formulations comprising dextran with molecular weight of 1.0-100kda and processes for their preparation
AU2007206087A AU2007206087A1 (en) 2006-01-18 2007-01-17 Pharmaceutical formulations comprising dextran with molecular weight of 1.0-100kDa and processes for their preparation
CA002636173A CA2636173A1 (en) 2006-01-18 2007-01-17 Pharmaceutical formulations comprising dextran with molecular weight of 1.0-100kda and processes for their preparation
DE602007003315T DE602007003315D1 (de) 2006-01-18 2007-01-17 Pharmazeutische formulierungen mit dextran mit einem molekulargewicht von 1,0-100 kda und herstellungsverfahren dafür
RU2008133635/15A RU2008133635A (ru) 2006-01-18 2007-01-17 Способы и композиции
EP09175832A EP2153850A1 (en) 2006-01-18 2007-01-17 Liquid compositions comprising dextran, in situ formed implants obtained thereof
CNA2007800026635A CN101370523A (zh) 2006-01-18 2007-01-17 方法和组合物
AT07709420T ATE448798T1 (de) 2006-01-18 2007-01-17 Pharmazeutische formulierungen mit dextran mit einem molekulargewicht von 1,0-100 kda und herstellungsverfahren dafür
BRPI0706543-4A BRPI0706543A2 (pt) 2006-01-18 2007-01-17 processo para preparação de uma composição adequada para a liberação controlada, e, artigo para aplicação biomédica
EP07709420A EP1973570B1 (en) 2006-01-18 2007-01-17 Pharmaceutical formulations comprising dextran with molecular weight of 1.0-100kda and processes for their preparation
US12/161,324 US20080305139A1 (en) 2006-01-18 2007-01-17 Pharmaceutical Compositions Comprising Dextran with a Molecular Weight of 1.0-100 Kda and Processes for Their Preparation
MX2008008924A MX2008008924A (es) 2006-01-18 2007-01-17 Formulaciones farmaceuticas que comprenden dextrano con peso molecular de 1.0-100kda y procesos para su preparacion.
HK09103041.4A HK1125041B (en) 2006-01-18 2007-01-17 Pharmaceutical formulations comprising dextran with molecular weight of 1.0-100kda and processes for their preparation
ES07709420T ES2336380T3 (es) 2006-01-18 2007-01-17 Formulacion farmaceuticas que comprenden dextrano con un peso molecular de 1,0-100 kda y procedimiento para su preparacion.
JP2008551225A JP2009523791A (ja) 2006-01-18 2007-01-17 １．０〜１００ｋＤａの分子量を有するデキストランを含む薬剤及びその調製方法
ARP070100220A AR059071A1 (es) 2006-01-18 2007-01-18 Metodos y composicionesque comprenden dextrano con peso molecular de 1 a 100 kda
TW096101920A TW200738279A (en) 2006-01-18 2007-01-18 Method and compositions
US12/510,533 US7781400B2 (en) 2006-01-18 2009-07-28 Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 KDA and processes for their preparation
US12/724,158 US20100172950A1 (en) 2006-01-18 2010-03-15 Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 kda and processes for their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0600091A SE0600091L (sv) 2006-01-18 2006-01-18 Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin

Publications (2)

Publication Number Publication Date
SE529040C2 SE529040C2 (sv) 2007-04-17
SE0600091L true SE0600091L (sv) 2007-04-17

Family

ID=37930329

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0600091A SE0600091L (sv) 2006-01-18 2006-01-18 Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin

Country Status (16)

Country Link
US (3) US20080305139A1 (enExample)
EP (2) EP2153850A1 (enExample)
JP (1) JP2009523791A (enExample)
CN (1) CN101370523A (enExample)
AR (1) AR059071A1 (enExample)
AT (1) ATE448798T1 (enExample)
AU (1) AU2007206087A1 (enExample)
BR (1) BRPI0706543A2 (enExample)
CA (1) CA2636173A1 (enExample)
DE (1) DE602007003315D1 (enExample)
ES (1) ES2336380T3 (enExample)
MX (1) MX2008008924A (enExample)
RU (1) RU2008133635A (enExample)
SE (1) SE0600091L (enExample)
TW (1) TW200738279A (enExample)
WO (1) WO2007084068A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060015469A (ko) * 2003-03-04 2006-02-17 더 테크놀로지 디벨로프먼트 컴퍼니 리미티드 경구용 인슐린 조성물 및 그 제조방법 및 사용방법
US9023376B2 (en) * 2008-06-27 2015-05-05 The University Of Akron Nanofiber-reinforced composition for application to surgical wounds
KR101003331B1 (ko) 2010-05-11 2010-12-23 조강선 피부 충전제 조성물
JP6680682B2 (ja) * 2014-02-20 2020-04-15 オルト リジェネレイティヴ テクノロジーズ インク．Ｏｒｔｈｏ Ｒｅｇｅｎｅｒａｔｉｖｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． 凍結乾燥ポリマー骨格組成物、その製造方法及び同化的創傷修復における使用
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10426796B2 (en) * 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204244L (sv) 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
DE3500268A1 (de) * 1985-01-05 1986-07-10 Hoechst Ag, 6230 Frankfurt Praeparate mit verzoegerter wirkung, verfahren zu deren herstellung sowie entsprechende mittel zur human- bzw. veterinaermedizinischen anwendung
EP0247077A1 (en) 1985-10-22 1987-12-02 ROBINSON, Eric Process for cell immobilisation
JPS62152816A (ja) * 1985-12-27 1987-07-07 Sumitomo Pharmaceut Co Ltd ゲル状高分子の成形方法
JPH0720483B2 (ja) * 1987-05-29 1995-03-08 住友製薬株式会社 高粘度糊状組成物成形体の乾燥法
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US7087244B2 (en) 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
EP1074248A1 (en) 1999-07-08 2001-02-07 Arnold Hilgers Delivery system for biological material
AU4477001A (en) 2000-04-18 2001-10-30 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
EP1184032A1 (en) * 2000-08-31 2002-03-06 OctoPlus B.V. Dextran hydrogels
ES2280582T3 (es) 2001-09-19 2007-09-16 Elan Pharma International Limited Formulaciones de insulina en nanoparticulas.
KR20060015469A (ko) * 2003-03-04 2006-02-17 더 테크놀로지 디벨로프먼트 컴퍼니 리미티드 경구용 인슐린 조성물 및 그 제조방법 및 사용방법
TW200603843A (en) * 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method

Also Published As

Publication number Publication date
US20090281020A1 (en) 2009-11-12
EP2153850A1 (en) 2010-02-17
US20100172950A1 (en) 2010-07-08
SE529040C2 (sv) 2007-04-17
CN101370523A (zh) 2009-02-18
BRPI0706543A2 (pt) 2011-03-29
US7781400B2 (en) 2010-08-24
AU2007206087A1 (en) 2007-07-26
US20080305139A1 (en) 2008-12-11
WO2007084068A1 (en) 2007-07-26
ATE448798T1 (de) 2009-12-15
CA2636173A1 (en) 2007-07-26
JP2009523791A (ja) 2009-06-25
EP1973570A1 (en) 2008-10-01
DE602007003315D1 (de) 2009-12-31
TW200738279A (en) 2007-10-16
HK1125041A1 (en) 2009-07-31
RU2008133635A (ru) 2010-02-27
EP1973570B1 (en) 2009-11-18
ES2336380T3 (es) 2010-04-12
AR059071A1 (es) 2008-03-12
MX2008008924A (es) 2008-09-05

Similar Documents

Publication Publication Date Title
BRPI1013411A2 (pt) compósito biocompatível e seu uso
CL2009000889A1 (es) Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus.
WO2007066152A3 (en) Substance delivery device
CL2008001822A1 (es) Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
MY159865A (en) Aqueous insulin preparations containing methionine
CL2009001340A1 (es) Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto.
ZA201102350B (en) Pyridin-2-yl-amino-i,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
NO20091801L (no) Peristatisk mikropumpe med utskiftbart pumpehode
PE20090472A1 (es) Proceso para reducir la cantidad de componentes organicos en el agua usando carbonato de calcio que reacciona en la superficie en combinacion con un adsorbente hidrofobico, el cual se contacta con el agua a ser tratada
NZ604079A (en) Safety device for a pre-filled syringe and injection device
WO2008055118A3 (en) Methods and systems for immobilizing corneal prostheses
AR080884A1 (es) Conjugados de insulina-sirna
CY1113604T1 (el) Συστημα παροχης υγρου πολυμερους χαμηλου ιξωδους
CL2008002255A1 (es) Compuesto 3-({4-(2,2-difluoroetil)-3-(1h-pirrolo [2,3-b] piridin-5-il)-1h-pirazol-4-il] pirimidin-2-il}amino)propanonitrilo, inhibidor de raf; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del crecimiento celular anormal o cualquier enfermedad o afeccion mediada por raf.
WO2008063842A3 (en) Methods of treating neuropathic pain with agonists of ppar-gamma
WO2006133102A3 (en) Agent delivery system and uses of the same
AR080669A1 (es) Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
EP2270069A4 (en) CONJUGATED POLYMER, INSOLUBILIZED POLYMER, MATERIAL FOR ORGANIC ELECTROLUMINESCENZING DEVICE, COMPOSITION FOR ORGANIC ELECTROLUMINESCENZY DEVICE, PROCESS FOR PREPARING POLYMER, ORGANIC ELECTROLUMINESCENZING DEVICE, ORGANIC EL DISPLAY AND ORGANIC EL ILLUMINATOR
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
DE602006019517D1 (de) Multi-Nährstoff Polymerdüngemittel mit langsamer und gesteuerter Freigabe des Nährstoffs , Verfahren zu dessen Herstellung und Verwendung desselben
WO2006079641A3 (en) Insulin derivatives conjugated with structurally well defined branched polymers
ATE419842T1 (de) Abgabevehikel mit nanoteilchen
WO2010045506A3 (en) Sustained drug delivery system
EP4613284A3 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
BRPI0822580A2 (pt) Composto, recipiente, processo para produzir uma composição, uso de uma composição, e, método para controle ou prevenção de doenças infecciosas.

Legal Events

Date Code Title Description
NUG Patent has lapsed